Details of the Drug Combination

General Information of Drug Combination (ID: DCEU140)

Drug Combination Name
LIAROZOLE ER819762
Indication
Disease Entry Status REF
Breast adenocarcinoma Investigative [1]
Component Drugs LIAROZOLE   DM4OYXE ER819762   DMSG91J
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: MDA-MB-468
Zero Interaction Potency (ZIP) Score: 5.09
Bliss Independence Score: 4.83
Loewe Additivity Score: 4.3
LHighest Single Agent (HSA) Score: 4.55

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of LIAROZOLE
Disease Entry ICD 11 Status REF
Dermatological disease DA24.Y Phase 2/3 [2]
LIAROZOLE Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Aromatase (CYP19A1) TTSZLWK CP19A_HUMAN Inhibitor [4]
Cytochrome P450 26 (CYP26A1) TTD7Q0R CP26A_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Indication(s) of ER819762
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [3]
ER819762 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Prostaglandin E2 receptor EP4 (PTGER4) TT79WV3 PE2R4_HUMAN Antagonist [6]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult acute myeloid leukemia DCKKIB9 HL-60(TB) Investigative [7]
Adult T acute lymphoblastic leukemia DCSO0X5 MOLT-4 Investigative [7]
Childhood T acute lymphoblastic leukemia DCLSRPL CCRF-CEM Investigative [7]
Invasive ductal carcinoma DC23DSP HS 578T Investigative [1]
Adenocarcinoma DC0YIIZ DU-145 Investigative [8]
Adenocarcinoma DC8RJG8 A549 Investigative [8]
Amelanotic melanoma DCW55VB MDA-MB-435 Investigative [8]
Large cell lung carcinoma DC8Q9TT NCI-H460 Investigative [8]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DrugCom(s)

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5210).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4040).
4 Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
5 Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells. Bioorg Med Chem. 2008 Sep 1;16(17):8301-13.
6 A novel antagonist of the prostaglandin E(2) EP(4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. Br J Pharmacol. 2010 May;160(2):292-310.
7 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
8 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976